Genscript Biotech (OTCMKTS:GNNSF) Trading Down 21.5% – What’s Next?

Genscript Biotech Co. (OTCMKTS:GNNSF)’s stock price traded down 21.5% during mid-day trading on Monday . The company traded as low as C$1.67 and last traded at C$1.67. 10,000 shares were traded during trading, an increase of 199% from the average session volume of 3,345 shares. The stock had previously closed at C$2.12.

Genscript Biotech Price Performance

The company has a 50-day simple moving average of C$2.13 and a two-hundred day simple moving average of C$2.15.

About Genscript Biotech

GenScript Biotech Corporation is a global contract research, development and manufacturing organization (CDMO) specializing in synthetic biology and biopharmaceutical services. Founded in 2002, the company provides end-to-end solutions that span gene and peptide synthesis, recombinant protein expression, custom antibody discovery and cell line development. GenScript’s integrated platforms support early-stage discovery through to process development, enabling academic institutions, biotech innovators and pharmaceutical companies to accelerate research timelines.

The company’s core offerings include molecular biology services such as DNA construction, gene editing using CRISPR/Cas9 technology and high-throughput peptide libraries.